Catrina Bourne
Family Medicine · Yukon, OKNPI 1174562763
Payments from drug & device makers
Across 399 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$863
- Pfizer$638
- Novo Nordisk$621
- AbbVie$462
- GSK$450
- Bayer$444
- plus $4K from 38 others
What the payments were for
- Food & beverage$7,37299%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,437 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 56 | $59,213 |
| OzempicSemaglutide | 17 | $15,631 |
| QuliptaAtogepant | 14 | $14,669 |
| JardianceEmpagliflozin | 14 | $11,707 |
| FarxigaDapagliflozin Propanediol | 19 | $10,644 |
| EliquisApixaban | 12 | $7,848 |
| Solifenacin Succinate | 38 | $2,622 |
| Olmesartan Medoxomil | 29 | $1,482 |
| Celecoxib | 35 | $1,147 |
| Rosuvastatin Calcium | 27 | $985 |
| Levothyroxine Sodium | 85 | $900 |
| Omeprazole | 32 | $664 |
| ProgesteroneProgesterone, Micronized | 15 | $598 |
| Duloxetine Hcl | 15 | $523 |
| Gabapentin | 29 | $437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $414 | $59,21356 claims |
| Novo NordiskOzempic | $621 | $15,63117 claims |
| AbbVieQulipta | $462 | $14,66914 claims |
| Boehringer IngelheimJardiance | $238 | $11,70714 claims |
| AstraZenecaFarxiga | $330 | $10,64419 claims |
| PfizerEliquis | $638 | $7,84812 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $18815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Yukon
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.